Zanubrutinib Versus Bendamustine and Rituximab in Patients With Treatment-Naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Median 5-Year Follow-Up of SEQUOIA

Molecule: Zanubrutinib

12 Dec 2024

BGB-3111-215 (NCT04116437) is a Phase 2, multicenter, single-arm trial of zanubrutinib in patients with previously treated B-cell lymphoma intolerant of prior treatment with ibrutinib and/or acalabrutinib.

Reading
6 Dec 2024

ROSEWOOD (NCT03332017) is a Phase 2, open-label, randomized trial of zanubrutinib combined with obinutuzumab compared with obinutuzumab monotherapy in patients with relapsed/refractory (R/R) follicular lymphoma (FL).

Reading
6 Dec 2024

BGB-3111-206 (NCT03206970) is a Phase 2, multicenter, single-arm, open-label trial of zanubrutinib in patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL).

Reading
6 Dec 2024

MAGNOLIA (NCT03846427) is a Phase 2, multicenter, open-label, single-arm trial of zanubrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL).

Reading
6 Dec 2024